Instituto Bioclon
The Instituto Bioclon S.A. de C.V. was formed in 1990 to research and develop F2 antivenoms. On May 6, 2015 they received approval from the FDA to commercialize Anavip becoming their second drug approved by the FDA after ANASCORP. Both are commercialized in the US by Rare Disease Therapeutics, Inc. The company is performing clinical trials to get approval for a third drug, ANALATRO, designed to treat black widow spider envenomation.
Operations
The Instituto Bioclon is located in Mexico City, Mexico and has a Certificación Internacional de Buenas Prácticas de Manufactura which was granted to Bioclon by the,, of the Ministry of Health and Social Protection of Colombia, as well as by COFEPRIS, in Mexico.Products
- Anavip – timber rattlesnake antivenom
- Coralmyn – coral snake antivenom
- Antivipmyn – pit viper antivenom
- Antivipmyn TRI – Central and South American snakes
- Antivipmyn Africa – African snakes
- Alacramyn – scorpion antivenom
- Reclusmyn – brown recluse antivenom
- Aracmyn – black widow antivenom